Twitter | Search | |
DepMap
The Cancer Dependency Map at Broad Institute systematically identifies genes and small molecule dependencies and determines the markers that predict sensitivity
181
Tweets
234
Following
1,498
Followers
Tweets
DepMap Mar 26
Replying to @CancerDepMap
Celligner can be used to select models that best represent a tumor type of interest, as well as to identify gaps in our current cell line representation of patient tumors. More broadly, we hope this tool can help bridge the gaps between preclinical and clinical cancer datasets!
Reply Retweet Like
DepMap Mar 26
Replying to @CancerDepMap
Using Celligner we also identified several hundred cell lines, spanning diverse lineages, characterized by an undifferentiated transcriptional state not seen in the primary tumor datasets, and these cell lines exhibited unique genetic and chemical vulnerabilities.
Reply Retweet Like
DepMap Mar 26
Replying to @CancerDepMap
We used Celligner to integrate more than 13,000 tumor and cell line samples across 36 cancer types in an unbiased manner, revealing close alignment for some transcriptional (sub)types but systematic differences in others.
Reply Retweet Like
DepMap Mar 26
We’re excited to share a preprint of our manuscript describing a computational approach (Celligner) for integrating tumor and cell line gene expression datasets. Check out the preprint () and explore the integrated data here: .
Reply Retweet Like
DepMap Mar 24
We're making the most of WFH! CDS launched its blog today! Follow for more insight into DepMap data and analysis in the weeks ahead.
Reply Retweet Like
DepMap Feb 25
We're excited to share our latest research exploring the power of gene expression to predict cancer vulnerabilities! Great work Josh and team!
Reply Retweet Like
DepMap retweeted
Pardis Sabeti Feb 11
Reply Retweet Like
DepMap Feb 7
D'oh! let's get that fixed! 🙃
Reply Retweet Like
DepMap Feb 7
New 20Q1 now available! Data for 44 new cell lines, plus newly integrated proteomics data from +
Reply Retweet Like
DepMap Feb 7
New 20Q1 now available! Data for 44 new cell lines, plus newly integrated proteomics data from +
Reply Retweet Like
DepMap retweeted
David R. Liu Jan 28
Replying to @SuperScienceGrl
Venerable genetic code? OK, boomer.
Reply Retweet Like
DepMap retweeted
Francisca Vazquez Jan 23
Congrats David! This will be a great resource for depmap!
Reply Retweet Like
DepMap Jan 21
Happy data digging! ⛏️
Reply Retweet Like
DepMap Jan 21
Explore the data on the landing page of the paper (), or look for correlations with other data on Data Explorer () or the Dose Curves tab ()!
Reply Retweet Like
DepMap Jan 21
Congratulations to on the Drug Repurposing paper published today ! An unexpectedly large number of non-oncology drugs selectively inhibit subsets of cancer cell lines:
Reply Retweet Like
DepMap retweeted
Broad Institute Jan 20
Researchers from Broad and scanned thousands of drugs in hundreds of cell lines and found that dozens of non-oncology drugs can unexpectedly kill cells
Reply Retweet Like
DepMap Jan 15
Do you care about , cross cutting collaborations, and cancer patient impact? Join the DepMap team! We are for a Project Coordinator, apply here:
Reply Retweet Like
DepMap Jan 14
Woah! Our recent joint paper with showing concordance in our data was covered by The :
Reply Retweet Like
DepMap retweeted
Anirban Maitra Jan 10
There’s a lot of chatter online about getting a “secret miracle treatment” for because of her “special” status. If there truly was a miracle Rx for this cancer, it would NOT be a secret. There would be press releases & FDA would approve it overnight!
Reply Retweet Like
DepMap retweeted
Nature Communications Jan 3
. show that the two largest independent CRISPR-Cas9 gene-dependency screens are concordant, paving the way for their joint analysis.
Reply Retweet Like